AU2001243657A1 - Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor - Google Patents
Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitorInfo
- Publication number
- AU2001243657A1 AU2001243657A1 AU2001243657A AU4365701A AU2001243657A1 AU 2001243657 A1 AU2001243657 A1 AU 2001243657A1 AU 2001243657 A AU2001243657 A AU 2001243657A AU 4365701 A AU4365701 A AU 4365701A AU 2001243657 A1 AU2001243657 A1 AU 2001243657A1
- Authority
- AU
- Australia
- Prior art keywords
- growth factor
- inhibitor
- combined treatment
- epidermal growth
- keratinocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title abstract 4
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19069700P | 2000-03-20 | 2000-03-20 | |
US60190697 | 2000-03-20 | ||
PCT/US2001/008207 WO2001070255A2 (en) | 2000-03-20 | 2001-03-15 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001243657A1 true AU2001243657A1 (en) | 2001-10-03 |
Family
ID=22702391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001243657A Abandoned AU2001243657A1 (en) | 2000-03-20 | 2001-03-15 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
Country Status (12)
Country | Link |
---|---|
US (3) | US20020061304A1 (en) |
EP (1) | EP1276496B1 (en) |
JP (1) | JP2003527437A (en) |
AT (1) | ATE297751T1 (en) |
AU (1) | AU2001243657A1 (en) |
CA (1) | CA2403721C (en) |
DE (1) | DE60111515T2 (en) |
ES (1) | ES2240430T3 (en) |
MX (1) | MXPA02009176A (en) |
MY (1) | MY124799A (en) |
TW (1) | TWI281402B (en) |
WO (1) | WO2001070255A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706721B1 (en) * | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
UA74803C2 (en) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
AU2006236633B2 (en) * | 2005-04-15 | 2012-03-29 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy |
CA2656613A1 (en) * | 2006-07-03 | 2008-01-10 | Genmab A/S | Prevention of rash in patients undergoing anti-egfr therapy |
DE102007026877A1 (en) * | 2007-06-08 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Use of fibroblast growth factor 7 (Fgf7) and the receptor Fgfr2b as biomarkers |
US8815953B2 (en) * | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
WO2017162604A1 (en) | 2016-03-21 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treatment of solar lentigo |
CN111601617A (en) | 2017-12-13 | 2020-08-28 | 上海岸阔医药科技有限公司 | Method for preventing or treating diseases related to EGFR inhibition |
TW201943428A (en) | 2018-04-16 | 2019-11-16 | 大陸商上海岸闊醫藥科技有限公司 | Method for preventing or treating side effects of cancer therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN271295A0 (en) | 1995-05-02 | 1995-05-25 | Gropep Pty Ltd | Method of treatment |
HU220641B1 (en) * | 1993-03-26 | 2002-03-28 | Amgen Inc. | Uses of keratinocyte growth factor |
DK0815115T3 (en) * | 1995-02-14 | 2003-09-15 | Human Genome Sciences Inc | Keratinocyte growth factor-2 |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
2001
- 2001-03-15 WO PCT/US2001/008207 patent/WO2001070255A2/en active IP Right Grant
- 2001-03-15 MX MXPA02009176A patent/MXPA02009176A/en active IP Right Grant
- 2001-03-15 CA CA002403721A patent/CA2403721C/en not_active Expired - Fee Related
- 2001-03-15 ES ES01916662T patent/ES2240430T3/en not_active Expired - Lifetime
- 2001-03-15 AT AT01916662T patent/ATE297751T1/en not_active IP Right Cessation
- 2001-03-15 US US09/808,751 patent/US20020061304A1/en not_active Abandoned
- 2001-03-15 MY MYPI20011208A patent/MY124799A/en unknown
- 2001-03-15 DE DE60111515T patent/DE60111515T2/en not_active Revoked
- 2001-03-15 JP JP2001568452A patent/JP2003527437A/en active Pending
- 2001-03-15 EP EP01916662A patent/EP1276496B1/en not_active Revoked
- 2001-03-15 AU AU2001243657A patent/AU2001243657A1/en not_active Abandoned
- 2001-03-20 TW TW90106475A patent/TWI281402B/en not_active IP Right Cessation
-
2003
- 2003-06-10 US US10/458,072 patent/US7402557B2/en not_active Expired - Fee Related
-
2008
- 2008-04-30 US US12/150,745 patent/US20080206257A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60111515T2 (en) | 2006-05-11 |
EP1276496B1 (en) | 2005-06-15 |
CA2403721A1 (en) | 2001-09-27 |
EP1276496A2 (en) | 2003-01-22 |
JP2003527437A (en) | 2003-09-16 |
US7402557B2 (en) | 2008-07-22 |
ES2240430T3 (en) | 2005-10-16 |
CA2403721C (en) | 2009-06-09 |
DE60111515D1 (en) | 2005-07-21 |
MY124799A (en) | 2006-07-31 |
WO2001070255A2 (en) | 2001-09-27 |
ATE297751T1 (en) | 2005-07-15 |
US20080206257A1 (en) | 2008-08-28 |
US20040071697A1 (en) | 2004-04-15 |
WO2001070255A3 (en) | 2002-02-28 |
MXPA02009176A (en) | 2004-08-12 |
TWI281402B (en) | 2007-05-21 |
US20020061304A1 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001243657A1 (en) | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | |
UA56989C2 (en) | PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES | |
AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
SI1278549T1 (en) | Composition containing a cyclodextrin and a glycopeptide antibiotic | |
IL149176A0 (en) | Therapeutic use | |
BR0309343A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
BR0309342A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
MX2020009149A (en) | Compounds including a mutant kras sequence and a lipid and uses thereof. | |
HUP0202776A2 (en) | Use of (+)-tramadol, o-demethyltramadol or(+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for preparation pharmaceutical composition available for treating urinary incontinence | |
IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
AU2003205768A1 (en) | Methods and compositions for treating hyperproliferative conditions | |
AU2003217982A1 (en) | Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol | |
AU2003244762A1 (en) | Methods and compositions for intravesical therapy of bladder cancer | |
BR0311491A (en) | Compound, Pharmaceutical Composition, Use of a Compound, and, Therapeutic Method to Treat Cancer in a Mammal | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
TNSN04235A1 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
MY135460A (en) | Method of stimulating hair growth using benzopyrans | |
AU2001246388A1 (en) | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine | |
HK1085744A1 (en) | Steroid compounds with anti-tumor activity | |
DE50109320D1 (en) | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR THE THERAPY OF HARNINE INCONTINENCE | |
WO2003103614A3 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
MXPA05003633A (en) | 2" oxo-voruscharin and derivatives thereof. | |
AU2002211217A1 (en) | Method of treating stroke | |
AU2001262378A1 (en) | Method for treating cryptorchidism | |
MXPA04005265A (en) | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation. |